Does Preoperative MELD Score Predict Adverse Outcomes Following Pancreatic Resection: an ACS NSQIP Analysis

  • Amr I. Al Abbas
  • Jeffrey D. Borrebach
  • Johanna Bellon
  • Amer H. ZureikatEmail author
Original Article



Higher MELD scores correlate with adverse operative outcomes regardless of the presence of liver disease, but their impact on pancreatectomy outcomes remains undefined. We aimed to compare 30-day adverse postoperative outcomes of patients undergoing elective pancreatectomy stratified by MELD score.


Elective pancreatoduodenectomies (PDs) and distal pancreatectomies (DPs) were identified from the 2014–2016 ACS NSQIP Procedure Targeted Pancreatectomy Participant Use Data Files. Outcomes examined included mortality, cardiopulmonary complications, prolonged postoperative length-of-stay, discharge not-to-home, transfusion, POPF, CR-POPF, any complication, and serious complication. Outcomes were compared between MELD score strata (< 11 vs. ≥ 11) as established by the United Network for Organ Sharing (UNOS). Multivariable logistic regression models were constructed to examine the risk-adjusted impact of MELD score on outcomes.


A total of 7580 PDs and 3295 DPs had evaluable MELD scores. Of these, 1701 PDs and 223 DPs had a MELD score ≥ 11. PDs with MELD ≥ 11 exhibited higher risk for mortality (OR = 2.07, p < 0.001), discharge not-to-home (OR = 1.26, p = 0.005), and transfusion (OR = 1.7, p < 0.001). DP patients with MELD ≥ 11 demonstrated prolonged LOS (OR = 1.75, p < 0.001), discharge not-to-home (OR = 1.83, p = 0.01), and transfusion (OR = 2.78, p < 0.001). In PD, MELD ≥ 11 was independently predictive of 30-day mortality (OR = 1.69, p = 0.007) and transfusion (OR = 1.55, p < 0.001). In DP, MELD ≥ 11 was independently predictive of prolonged LOS (OR = 1.42, p = 0.026) and transfusion (OR = 2.3, p < 0.001).


A MELD score ≥ 11 is associated with a near twofold increase in the odds of mortality following pancreatoduodenectomy. The MELD score is an objective assessment that aids in risk-stratifying patients undergoing pancreatectomy.


Pancreatectomy Pancreatoduodenectomy Distal pancreatectomy Liver disease MELD 


Compliance with Ethical Standards

Conflict of Interest

The authors have declare that they have no conflicts of interest.

Supplementary material

11605_2019_4380_MOESM1_ESM.docx (28 kb)
ESM 1 (DOCX 27 kb)


  1. 1.
    Chu CK, Mazo AE, Sarmiento JM, Staley CA, Adsay NV, Umpierrez GE et al. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma. J Am Coll Surg. 2010;210(4):463–73. doi: Scholar
  2. 2.
    Greenblatt DY, Kelly KJ, Rajamanickam V, Wan Y, Hanson T, Rettammel R et al. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol. 2011;18(8):2126–35. doi: Scholar
  3. 3.
    House MG, Fong Y, Arnaoutakis DJ, Sharma R, Winston CB, Protic M et al. Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg. 2008;12(2):270–8. doi: Scholar
  4. 4.
    Kelly KJ, Greenblatt DY, Wan Y, Rettammel RJ, Winslow E, Cho CS et al. Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. J Gastrointest Surg. 2011;15(2):250–9, discussion 9-61. doi: Scholar
  5. 5.
    Lillemoe KD, Kaushal S, Cameron JL, Sohn TA, Pitt HA, Yeo CJ. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg. 1999;229(5):693–8; discussion 8-700.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013;5:1–10. doi: Scholar
  7. 7.
    Nicoll A. Surgical risk in patients with cirrhosis. J Gastroenterol Hepatol. 2012;27(10):1569–75. doi: Scholar
  8. 8.
    Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.PubMedGoogle Scholar
  9. 9.
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71. doi: Scholar
  11. 11.
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70. doi: Scholar
  12. 12.
    Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo End-stage Liver Disease. Hepatology. 2001;33(2):473–5. doi: Scholar
  13. 13.
    Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40(6):897–903. doi: Scholar
  14. 14.
    Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6. doi: Scholar
  15. 15.
    Casadaban LC, Gabra MG, Parvinian A, Minocha J, Knuttinen MG, Bui JT et al. Impact of transjugular intrahepatic portosystemic shunt creation on intermediate-term model for end-stage liver disease score progression. Transplant Proc. 2014;46(5):1384–8. doi: Scholar
  16. 16.
    Jacob M, Copley LP, Lewsey JD, Gimson A, Toogood GJ, Rela M et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland. Liver Transpl. 2004;10(7):903–7. doi: Scholar
  17. 17.
    Lange EO, Jensen CC, Melton GB, Madoff RD, Kwaan MR. Relationship between model for end-stage liver disease score and 30-day outcomes for patients undergoing elective colorectal resections: an American college of surgeons-national surgical quality improvement program study. Dis Colon Rectum 2015;58(5):494–501. doi: Scholar
  18. 18.
    Lopez-Delgado JC, Esteve F, Javierre C, Ventura JL, Manez R, Farrero E et al. Influence of cirrhosis in cardiac surgery outcomes. World J Hepatol. 2015;7(5):753–60. doi: Scholar
  19. 19.
    Millwala F, Nguyen GC, Thuluvath PJ. Outcomes of patients with cirrhosis undergoing non-hepatic surgery: risk assessment and management. World J Gastroenterol. 2007;13(30):4056–63.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Minhem MA, Sarkis SF, Safadi BY, Fares SA, Alami RS. Comparison of Early Morbidity and Mortality Between Sleeve Gastrectomy and Gastric Bypass in High-Risk Patients for Liver Disease: Analysis of American College of Surgeons National Surgical Quality Improvement Program. Obes Surg. 2018;28(9):2844–51. doi: Scholar
  21. 21.
    Morimoto N, Okada K, Okita Y. The model for end-stage liver disease (MELD) predicts early and late outcomes of cardiovascular operations in patients with liver cirrhosis. Ann Thorac Surg. 2013;96(5):1672–8. doi: Scholar
  22. 22.
    Northup PG, Wanamaker RC, Lee VD, Adams RB, Berg CL. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg. 2005;242(2):244–51.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Causey MW, Nelson D, Johnson EK, Maykel J, Davis B, Rivadeneira DE et al. The impact of Model for End-Stage Liver Disease-Na in predicting morbidity and mortality following elective colon cancer surgery irrespective of underlying liver disease. Am J Surg. 2014;207(4):520–6. doi: Scholar
  24. 24.
    Hedrick TL, Swenson BR, Friel CM. Model for End-stage Liver Disease (MELD) in predicting postoperative mortality of patients undergoing colorectal surgery. Am Surg. 2013;79(4):347–52.PubMedGoogle Scholar
  25. 25.
    Kantor O, Talamonti MS, Pitt HA, Vollmer CM, Riall TS, Hall BL et al. Using the NSQIP Pancreatic Demonstration Project to Derive a Modified Fistula Risk Score for Preoperative Risk Stratification in Patients Undergoing Pancreaticoduodenectomy. J Am Coll Surg. 2017;224(5):816–25. doi: Scholar
  26. 26.
    Kantor O, Pitt HA, Talamonti MS, Roggin KK, Bentrem DJ, Prinz RA et al. Minimally invasive pancreatoduodenectomy: is the incidence of clinically relevant postoperative pancreatic fistula comparable to that after open pancreatoduodenectomy? Surgery. 2018;163(3):587–93. doi: Scholar
  27. 27.
    del Olmo JA, Flor-Lorente B, Flor-Civera B, Rodriguez F, Serra MA, Escudero A et al. Risk factors for nonhepatic surgery in patients with cirrhosis. World J Surg. 2003;27(6):647–52. doi: Scholar
  28. 28.
    Venkat R, Puhan MA, Schulick RD, Cameron JL, Eckhauser FE, Choti MA et al. Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: a novel scoring system. Arch Surg. 2011;146(11):1277–84. doi: Scholar
  29. 29.
    Are C, Afuh C, Ravipati L, Sasson A, Ullrich F, Smith L. Preoperative nomogram to predict risk of perioperative mortality following pancreatic resections for malignancy. J Gastrointest Surg. 2009;13(12):2152–62. doi: Scholar
  30. 30.
    Hill JS, Zhou Z, Simons JP, Ng SC, McDade TP, Whalen GF et al. A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Ann Surg Oncol. 2010;17(7):1802–7. doi: Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  • Amr I. Al Abbas
    • 1
  • Jeffrey D. Borrebach
    • 2
  • Johanna Bellon
    • 2
  • Amer H. Zureikat
    • 1
    • 3
    Email author
  1. 1.University of Pittsburgh Medical CenterPittsburghUSA
  2. 2.The Wolff Center at UPMCPittsburghUSA
  3. 3.Division of GI Surgical Oncology, UPMC Pancreatic Cancer CenterUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations